GLP1s: Wegovy, Zepbound, and Ozempic

Ozempic, Zepbound and Wegovy

Ozempic is the brand name for semaglutide, a medication that belongs to a class called glucagon-like peptide 1 (GLP-1) receptor agonists. For simplicity, these are often referred to as "GLP-1s." Zepbound contains the same active ingredient as Mounjaro®—tirzepatide, which is a dual-action GLP-1/GIP receptor agonist. It’s FDA-approved for people with obesity or those who are overweight and have a weight-related health condition, in addition to diet and exercise changes.

While Zepbound and Wegovy are FDA-approved for weight loss, Ozempic is approved for managing type 2 diabetes but can also be prescribed off-label for weight loss, if suitable.

The key difference between these medications lies in their active ingredients. Ozempic and Wegovy use semaglutide, while Zepbound contains tirzepatide. Tirzepatide works by activating two receptors, GLP-1 and GIP, which helps reduce nausea and regulate metabolism, promoting feelings of fullness for a longer time. In contrast, semaglutide only targets the GLP-1 receptor.